FY26 represents a major rebound year for the CDMRPs, restoring funding to $1.27B after FY25’s cut to $650M, and bringing back a nearly full portfolio of 34 programs. This restoration returns CDMRP mechanisms, award opportunities, and program diversity to levels much closer to FY24. Overall, FY26 reestablishes broad biomedical investment, revives critical disease and readiness related research areas, and expands strategic priorities such as psychological health. Contact us and start planning your FY26 submission!

Joint Warfighter Medical Research Program

Toxic Exposures Research Program

Military Burn Research Program

Bone Marrow Failure Research Program

Duchenne Muscular Dystrophy Research Program

Parkinson's Research Program

Peer Reviewed Medical Research Program

Traumatic Brain Injury and Psychological Health Research Program

Epilepsy Research Program

Alzheimer's Research Program

Autism Research Program

Lung Cancer Research Program

Orthopaedic Research Program

Peer Reviewed Cancer Research Program

Hearing Restoration Research Program

Vision Research Program

Melanoma Research Program

Multiple Sclerosis Research Program

Tuberous Sclerosis Complex Research Program

Spinal Cord Injury Research Program

Amyotrophic Lateral Sclerosis Research Program

Arthritis Research Program

Ovarian Cancer Research Program

Pancreatic Cancer Research Program

Tick-Borne Disease Research Program

Lupus Research Program

Breast Cancer Research Program

Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA) - The PASA is offering four Research Mechanisms:

• RFA 8a/Planning Award - Period of Performance is 9-12 months, with a maximum Total Cost (indirect and direct) of $150,000.
• RFA 8b/Pre-Clinical Award - Period of Performance is 18 months, with a maximum Total Cost (indirect and direct) of $600,000.
• RFA 8c/Drug Discovery Award - Period of Performance is 24 months, with a maximum Total Cost (indirect and direct) of $600,000.
• RFA 8d/Expansion Award - Period of Performance is 12-24 months, with a maximum Total Cost (indirect and direct) of $250,000 to $750,000.

Compositional Learning-And-Reasoning for AI Complex Systems Engineering (CLARA) - CLARA is a DARPA fundamental research initiative focused on creating high‑assurance AI systems by tightly integrating machine learning (ML) and automated reasoning (AR) into unified, verifiable architectures.

CLARA is structured into two major technical areas:

• TA1 — High‑Assurance ML/AR Approaches: Create new compositional methods, theories, and open‑source tools for integrating ML and AR.
• TA2 — Software Composition Library: Build a shared framework to integrate and validate TA1 tools.

The technology will support a wide range of high‑stakes environments, including:

• Autonomous systems & command‑and‑control
• Supply chain & logistics
• Kill web / wargaming
• Medical, financial, and legal decision systems
• Science & technology design

Full Proposals Due: April 10, 2026, 4:00 PM ET

SBIR - Unbiased Behavioral Discovery Platforms The Unbiased Behavioral Discovery Platforms program focuses on developing automated, unguided behavioral discovery technologies to accelerate early threat detection and medical countermeasure (MCM) development for chemical, biological, radiological, and nuclear (CBRN) threats.

Request for Information: CPE CBRND Seeking Device Capable of Delivering Medical Countermeasure via Inhalation and Intramuscular Routes

Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials

Complex Geometries for Extended Wear Respirators Towards Regenerable Particulate Matter Protection

Integrated Deployable Microsensors for Chemical Detection

Far Forward Manufacturing of CBRN Sensors

OPEN TOPIC - Tactical CB Visualization

Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics

OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)

Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)

Novel Technologies for CWMD and Related Threats - Open Topic Related Threats

Novel Technologies for CWMD and Related Threats - Open Topicd Related Threats

MCDC Consortium:

MCDC Forecasted Opportunity: Consolidated Nerve Agent Treatment System (CNATS): This is a follow-on Development Award to develop and deliver a multi-drug autoinjector by leveraging already, or soon to be approved, platforms to unencumber the warfighter to treat when faced with a nerve agent exposure. The product will increase survivability of the warfighter.

RFI: Prophylaxis in Advanced Development 

CPE CBRND is conducting essential market research for the Prophylaxis in Advanced Development (PAD) program, a new initiative expected to launch in Fiscal Year 2028. This program is dedicated to identifying and advancing high-impact innovative prophylactic candidates that can provide reliable, mission-enabling protection for our military personnel against both endemic and weaponized pathogens as outlined in the Medical Management of Biologic Casualties Handbook.

Collaborations are being sought with innovative industry partners who are developing and commercializing cutting-edge solutions in the following areas:

Vaccines: Novel, durable candidates capable of delivering long-lasting immunity in operationally relevant environments. 

Chemoprophylactics: Field-stable formulation preferred via a practical route of administration (e.g., oral, inhalation, intranasal, injectable, sublingual, dermal patch). Products designed for reliable pre- and post-exposure protection in contested or resource-limited environments.

CPE CBRND is focused on mature candidates (preference to candidates that have completed Phase II).

White papers should not exceed three (3) pages. Responses to this RFI are due no later than April 17, 2026 by Noon EST. All submissions should be sent to mcdc@ati.org.

One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

The Advanced Research Projects Agency for Health (ARPA‑H) has released a major funding opportunity under its 1‑CURE program, a high‑risk, high‑reward initiative aimed at transforming cancer treatment. The program seeks to develop a single, rapid, low‑cost radiotherapy approach capable of treating all cancers, including metastatic and radiation‑resistant disease, potentially reducing treatment timelines from months to days. 

The 1‑CURE program focuses on integrating:

• Smart Radiotherapy Biomaterials (SRBs) that enhance immune response and improve radiation effectiveness, and
• An Abscopal Treatment Planning System (ATPS) that combines advanced treatment planning with ultra‑high dose rate (FLASH) radiotherapy to reliably trigger systemic anti‑tumor immune effects. 

ARPA‑H anticipates making multiple awards using flexible Other Transaction (OT) agreements to interdisciplinary teams spanning academia, industry, and clinical practice. 

Key Dates: 

• Funding Opportunity Published: March 16, 2026 
• Proposals Due: May 22, 2026 (11:59 PM ET) 
• Opportunity Closes: June 6, 2026 

More information, including FAQs and proposer resources, is available on the ARPA‑H 1‑CURE program page.

Delphi (Developing self-monitoring ecosystems to “know thyself”)

ARPA‑H has released a new funding opportunity under its DELPHI program, a high‑risk, high‑reward initiative aimed at enabling continuous, real‑time monitoring of deep biological signals outside of traditional clinical settings. The program seeks to accelerate development of scalable, low‑cost biosensing technologies that allow individuals and clinicians to better detect disease, manage treatments, and support recovery through improved physiological insight.

DELPHI focuses on the use of modular “chiplet” architecture, a flexible electronics approach that allows biosensing components to be mixed, matched, and rapidly integrated into wearable or ingestible devices. By reducing device size, weight, power requirements, and cost, the program aims to dramatically expand access to continuous monitoring of biomarkers such as hormones, inflammatory signals, and drug levels.

ARPA‑H anticipates making multiple awards using flexible Other Transaction (OT) agreements to multidisciplinary teams spanning biosensing, microelectronics, materials science, data systems, and clinical research.

Key Dates: 

• Funding Opportunity Published: March 10, 2026
• Solution Summaries Due: April 8, 2026
• Proposers’ Day: March 27, 2026 (virtual and in‑person)

More information, including FAQs and proposer resources, is available on the ARPA‑H DELPHI program webpage.

Critical Illness Immunological Reprogramming and Control Point Learning Engine

The CIRCLE program is an ARPA H funding initiative aimed at transforming critical care by developing technologies that can monitor, model, and modulate the immune system during life threatening illness. The goal is to move ICU care from reactive organ support to precision immune-guided intervention.

CIRCLE seeks proposals to build an integrated system that can:

1. Measure
   Capture dynamic, tissue-specific immune and inflammatory biomarkers in near real time.
2. Model
   Develop patient-specific computational “digital twins” to predict immune dysregulation and identify actionable control points.
3. Modulate
   Deliver targeted immune interventions—initially focusing on repurposing FDA approved therapies—to prevent organ failure and improve outcomes.

The program addresses the lack of tools to track the rapidly evolving immune response in critical illness and aims to reduce ICU length of stay, morbidity, mortality, and care costs. It is structured into three Technical Areas (Measure, Model, Modulate) supported by three Acceleration Platforms providing data infrastructure, regulatory-compliant testing, and clinical trial support.

Key Dates:

• Solution Summary Due: March 30, 2026, 1:00PM ET (A solution summary is required to submit a proposal)
• Proposal Due: May 28, 2026, 1:00PM ET

PCORI’s 2026 Topic Themes

Upcoming PCORI Funding Opportunities: Open April 1, 2026, 9 am (ET):

Addressing Sensory Health Needs Across the Lifespan PCORI Funding Announcement -- Cycle 2 2026 - 

Broad Pragmatic Studies PCORI Funding Announcement -- Cycle 2 2026

Phased Large Awards for Comparative Effectiveness Research PCORI Funding Announcement -- Cycle 2 2026

Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 2 2026

Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 2 2026

PCORI Call for Proposals for HSII Implementation Projects -- 2026 (HSII Participants Only)

Pfizer Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)

Pfizer Addressing HCP Knowledge Gaps in Baseline Assessments for Adults with Ulcerative Colitis Starting S1P Receptor Modulator Therapy

Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)

The Small Molecule Approaches for Rapid and Robust Treatment (SMART) Prize competition 

Forecast: Enhancing Understanding and Preparedness for Public Health Threats Through Research in Kenya